You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-GD2 monoclonal antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial in New York (beta-glucan, mAb 3F8, immunohistochemistry staining method)

Completed
  • Neuroblastoma
  • beta-glucan
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 4, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Neuroblastoma Trial in New York (anti-GD2 murine IgG3 mAb 3F8)

Completed
Has Results
  • Neuroblastoma
  • anti-GD2 murine IgG3 monoclonal antibody 3F8
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Apr 21, 2022

Neuroblastoma Trial in Madison, Southampton, London (Nivolumab, Ch14.18/CHO)

Recruiting
  • Neuroblastoma
  • Madison, Wisconsin
  • +2 more
Mar 28, 2022

Neuroblastoma Trial in Vienna, Berlin, Genova (ch14.18/CHO)

Completed
  • Neuroblastoma
  • Vienna, Austria
  • +2 more
Oct 21, 2020

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

Psoriasis Trial in Shanghai, Kunming (Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection, Placebo)

Active, not recruiting
  • Psoriasis
  • Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
  • Placebo
  • Shanghai, Shanghai, China
  • +2 more
Nov 7, 2022

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

SCLC Trial in United States (Nivatrotamab)

Terminated
  • SCLC
  • Tampa, Florida
  • +6 more
Jul 11, 2022

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
  • Najing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Sep 26, 2022

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

Recruiting
  • Non-Malignant Neoplasm
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 29, 2022

Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

Recruiting
  • Acute Gout
  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
  • +6 more
  • Wuhan, Hubei, China
  • +2 more
Oct 17, 2022

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

Anti-CGRP Monoclonal Antibody Response After Switching (AMARAS)

Recruiting
  • Migraine
  • Head Pain
    • Valladolid, Spain
      Hospital Clínico Universitario de Valladolid
    Mar 23, 2023

    Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

    Not yet recruiting
    • Primary Immune Thrombocytopenia (ITP)
    • TPO-RAs
    • TPO-RAs combining anti-CD 20 monoclonal antibody
    • Tianjin, China
      Institute of Hematology and Blood Diseases Hospital, Chinese Aca
    Feb 7, 2023

    Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular

    Completed
    • AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
    • Wenzhou, Zhejiang, China
      The First Affiliated Hospital of Wenzhou Medical University
    Nov 6, 2023

    Healthy Trial in Qingdao (VDJ001, Placebo)

    Completed
    • Healthy
    • Qingdao, Shandong, China
      the Affliated Hospital of Qingdao University
    Aug 30, 2023

    Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

    Recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +4 more
    • Necitumumab
    • +4 more
    • Los Angeles, California
      UCLA / Jonsson Comprehensive Cancer Center
    Jan 5, 2023

    Psoriasis Trial in Shanghai (608 Q2W, 608 Q4W, Placebo)

    Not yet recruiting
    • Psoriasis
    • 608 Q2W
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Huanshan Hospital Fudan University
    Sep 8, 2022

    Alzheimer Trial in United States (Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care)

    Not yet recruiting
    • Alzheimer Disease
    • Anti-amyloid Monoclonal Antibodies (mAbs)
    • Standard of Care
    • Albany, Georgia
    • +7 more
    Aug 13, 2023